RBC Capital Markets has revised its outlook for Galderma following the company's record H1 2026 sales of $3.13 billion and raised full-year guidance. The upgrade reflects strong execution across the injectables portfolio and accelerating demand in key markets.
Business & M&A
RBC Lifts Galderma Outlook Following H1 Beat
Analyst follows suit on revised guidance after record first-half sales.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
RBC revises Galderma estimates upward following record H1 sales and raised full-year guidance.
Galderma's ability to raise guidance mid-year signals confidence in sustained momentum through 2026, particularly in toxin and filler categories where GLP-1 weight-loss trends are driving both preventive and corrective aesthetic demand. For practice owners, analyst upgrades matter: they typically precede increased R&D investment, new product launches, and more aggressive rebate programs as manufacturers compete for market share. RBC's move suggests the Street expects Galderma to maintain pricing power and volume growth despite competitive pressure from AbbVie and Evolus.
Source: original report ↗
Frequently asked questions
Why are GLP-1 weight loss drugs driving demand for Botox and fillers?
GLP-1 users experience facial volume loss and skin laxity as they lose weight, creating demand for both preventive treatments (Botox to maintain results) and corrective procedures (fillers to restore volume). This dual-use trend is accelerating injectables sales across the industry, particularly benefiting Galderma's toxin and filler portfolio.
What does an analyst upgrade mean for medspa owners?
Analyst upgrades typically signal increased R&D investment, new product launches, and more aggressive rebate programs from manufacturers competing for market share. For practice owners, this usually means more favorable pricing, expanded product options, and stronger manufacturer support to drive volume.
How much did Galderma's H1 2026 sales increase?
Galderma reported record first-half 2026 sales of $3.13 billion and raised full-year guidance, reflecting strong execution across its injectables portfolio and accelerating demand in key markets.
Can Galderma maintain pricing power against AbbVie and Evolus competition?
RBC's analyst upgrade suggests the Street expects Galderma to maintain both pricing power and volume growth despite competitive pressure from AbbVie and Evolus, indicating confidence in the company's market position and product differentiation.
What does mid-year guidance revision tell us about Galderma's 2026 performance?
A mid-year guidance raise signals strong confidence in sustained momentum through the remainder of 2026, particularly in toxin and filler categories where demand is being driven by GLP-1 trends and broader aesthetic market growth.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.